SKL2001

909089-13-0

C14H14N4O3

DMSO : >= 96.66 mg/mL (337.63 mM)

Stem Cell/Wnt; Stem Cell/Wnt

SKL2001 is an agonist of the Wnt/beta-catenin pathway, with anti-cancer activity. IC50 & Target: Wnt/beta-catenin^[1] In Vitro: SKL2001 is an agonist of the Wnt/beta-catenin pathway, and also upregulates the expression of Axin2, a downstream target of the Wnt/beta-catenin pathway, but shows no effect on NF-kappaB, p53 reporter activity and GSK-3beta activity. SKL2001 causes osteoblast differentiation (20 and 40 uM) and suppresses preadipocyte differentiation (5, 10, and 30 uM) via the activation of the Wnt/beta-catenin pathway. SKL2001 (5, 10, and 30 uM) stabilizes intracellular beta-catenin in 3T3-L1 cells^[1]. SKL2001 (40 uM) significantly inhibits the proliferation of HCT116 spheroids independently of cytotoxicity and the inhibition is reversible; SKL2001 cuases cell cycle arrest in HCT116 spheroids. SKL2001 (40 uM) enhances round-shape spheroid formation and E-cadherin expression^[2].